Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients

References

• Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 286(18), 2211–2214 (2001).
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13, 1–10 (2000).
   PubMedGoogle Scholar
• Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nature Rev. Drug Discov. 2, 205–213 (2003).
   PubMed Web of Science ®Google Scholar
• Ross JS, Schenkein DP, Pietrusko R et al. Targeted therapies for cancer 2004. Am. J. Clin Pathol. 122, 598–609 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher ER, Anderson S, Dean S et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 103(1), 164–173 (2005).
   PubMed Web of Science ®Google Scholar
• Beselga J. Phase I and II clinical trials of trastuzumab. Ann. Oncol. 12(Suppl. 1), S49–S55 (2001).
   Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin. Oncol. 30(1), 30–38 (2003).
   PubMed Web of Science ®Google Scholar
• Brown RE, Lun M, Prichard JW, Blasick TM, Zhang PL. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann. Clin. Lab. Sci. 34(3), 251–262 (2004).
   PubMed Web of Science ®Google Scholar
• Lun M, Zhang PL, Siegelmann-Danieli N, Blasick TM, Brown RE. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-κB and p53 in breast cancer cell lines. Ann. Clin. Lab. Sci. 35(1), 15–24 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta Ak, McKenna WG, Weber CN et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8(3), 885–892 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang PL, Pelliteri PK, Law A et al. Overexpression of phosphorylated nuclear factor-κB (p-NF-κB) in tonsillar squamous cell carcinoma and high grade dysplasia is associated with poor prognosis. Mod. Pathol. (In Press).
   Google Scholar
• Lessard L, Mes-Masson A-M, Lamarre L, Wall L, Lattouf J-B, Saad F. NF-κB nuclear localization and its prognostic significance in prostate cancer. BJU Int. 91, 417–420 (2003).
   PubMed Web of Science ®Google Scholar
• Munn SE, Olliver L, Broadbent V, Pritchard J. Use of indomethacin in Langerhans cell histiocytosis. Med. Pediatr. Oncol. 32(4), 247–249 (1999).
   PubMedGoogle Scholar
• Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate. J. Pediatr. Hematol. Oncol. 23(1), 54–56 (2001).
   PubMedGoogle Scholar
• Brown RE. Interferon-α therapy, protein kinase C-α and Langerhans cell histiocytosis. Med. Pediatr. Oncol. 41, 63–64 (2003).
   PubMedGoogle Scholar
• Brown RE. Letter to the editor: cyclooxygenase-2 in osteolytic lesions of Langerhans cell histiocytosis. Med. Pediatr. Oncol. 34, 311 (2000).
   PubMedGoogle Scholar
• Brown RE. Letter to the editor: more on pamidronate in Langerhans’-cell histiocytosis. N. Engl. J. Med. 345, 1503 (2001).
   PubMedGoogle Scholar
• Brown RE. Brief communication: morphoproteomic analysis of osteolytic Langerhans cell histiocytosis with therapeutic implications. Ann. Clin. Lab. Sci. 35(2), 131–136 (2005).
   PubMed Web of Science ®Google Scholar
• Montella L, Insabato L, Pulmieri G. Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N. Engl. J. Med. 351, 1034–1035 (2004).
   PubMed Web of Science ®Google Scholar
• Hudelist G, Kostler WJ, Attems J et al. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br. J. Cancer 89(6), 983–991 (2003).
   PubMed Web of Science ®Google Scholar
• Thor A, Liu S, Edgerton S, Moore D, Stern D, DiGiovanna M. Activation (tyrosine phosphorylation) of ErbB-2 (HER2/neu) as a prognostic factor in node positive breast cancer: a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18, 3230–3239 (2000).
   PubMed Web of Science ®Google Scholar
• Stern DF. Phosphoproteomics. Exp. Molec. Pathol. 70, 327–331 (2001).
   PubMedGoogle Scholar
• Brown RE, Bostrom B, Zhang PL. Brief communication: morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann. Clin. Lab. Sci. 34(2), 203–205 (2004).
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang W, Bertram P, Zheng XF, McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int. J. Oncol. 24, 893–900 (2004).
   PubMed Web of Science ®Google Scholar
• Altomare DA, Wang HG, Skele KL et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23(34), 5853–5857 (2004).
   PubMed Web of Science ®Google Scholar
• Choe G, Horvath S, Cloughesy TF et al. Analysis of the phosphatidylinositol 3´-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63, 2742–2746 (2003).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
   PubMed Web of Science ®Google Scholar
• Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma group Phase II study. Eur. J. Cancer 39, 2006–2011 (2003).
   PubMed Web of Science ®Google Scholar
• McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr. Cancer Ther.3(4), 349–380 (2004).
   PubMedGoogle Scholar
• Brown RE. HER-2/neu-positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications. Ann. Clin. Lab. Sci. 32(1), 12–21 (2002).
   PubMedGoogle Scholar
• Girnita L, Wang M, Xie Y et al. Inhibition of N-linked glyosylation downregulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing’s sarcoma cells: therapeutic implications. Anticancer Drug Des. 15(1), 67–72 (2000).
   PubMedGoogle Scholar
• Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J. Cancer Res. Clin. Oncol. 129(11), 631–641 (2003).
   PubMedGoogle Scholar
• Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373(1), 231–241 (2000).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H,Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leukemia Lymphoma 45(11), 2187–2195 (2004).
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 44(2), 195–202 (2004).
   PubMed Web of Science ®Google Scholar
• Shah BH, Yesilkaya A, Olivares-Reyes JA, Chen HD, Hunyady L, Catt KJ. Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. Mol. Endocrinol. 18(8), 2035–2048 (2004).
   PubMedGoogle Scholar
• Garber K. Rapamycin’s resurrection: a new way to target the cancer cell cycle. JNCI Cancer Spectrum 93(20), 1517–1519 (2001).
   PubMedGoogle Scholar
• Huang S, Houghton PJ, Mechanisms of resistance to rapamycins. Drug Resist. Updat. 4(6), 378–391 (2001).
   PubMed Web of Science ®Google Scholar
• Carraway H, Hidalgo M. New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 6(5), 219–224 (2004).
   PubMed Web of Science ®Google Scholar
• Goudar RK, Shi Q, Hjelmeland MD et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE 788) and the mammalian target of rapamycin (RAD 001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. 4(1), 101–112 (2005).
   PubMed Web of Science ®Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev. 2, 727–739 (2002).
   Google Scholar
• Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21(10), 1980–1987 (2003).
   PubMed Web of Science ®Google Scholar
• Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol. Cell. Biol. 21(19), 6387–6394 (2001).
   PubMed Web of Science ®Google Scholar
• Graves LM, Han J, Earp HS III. Transactivation of the EGF receptor: is the PDGF receptor an unexpected accomplice? Mol. Interv. 2(4), 208–212 (2002).
   PubMedGoogle Scholar
• Chiu T, Santiskulvong C, Rozengurt E. EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 288(2), G182–G194 (2005).
   Google Scholar
• Gilmore AP, Valentijn AJ, Wang P et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 277(31), 27643–27650 (2002).
   PubMed Web of Science ®Google Scholar
• deJong JS, van Diest PJ, van der Valk P et al. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer, II: correlations with proliferation and angiogenesis. J. Pathol. 184, 53–57 (1998).
   PubMedGoogle Scholar
• Kawakami Y, Kitaura J, Yao L et al. A Ras activation pathway dependent on Syk phosphorylation of protein kinase C. Proc. Natl Acad. Sci. USA 100(16), 9470–9475 (2003).
   PubMedGoogle Scholar
• Shao J, Evers BM, Sheng H. Roles of phosphatidylinositol 3´-kinase and mammalian target to rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 64(1), 229–235 (2004).
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Ohmichi M, Kimura A et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J. Biol. Chem. 277(36), 33490–33500 (2002).
   PubMed Web of Science ®Google Scholar
• Tsutsumi N, Yonemitsu Y, Shikada Y et al. Essential role of PDGFR-α-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFR α during angiogenesis. Circulation Res. 94, 1186–1194 (2004).
   PubMedGoogle Scholar
• Gao N, Flynn DC, Zhang Z et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/Akt/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. 287, C281–C291 (2004).
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 140(10), 4659–4668 (1999).
   PubMed Web of Science ®Google Scholar
• Morley SJ. Signaling through either the p38 or ERK mitogen-activated protein (MAP) kinase pathway is obligatory for phorbol ester and T-cell receptor complex (TCR-CD3)-stimulated phosphorylation of initiation factor (eIF) 4E in Jurkat T-cells. FEBS Lett. 418(3), 327–332 (1997).
   PubMedGoogle Scholar
• Herbert TP, Tee AR, Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J. Biol. Chem. 277(13), 11591–11596 (2002).
   PubMedGoogle Scholar
• Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidylinositol 3-kinase and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J. Biol. Chem. 279(2), 1010–1019 (2004).
   PubMedGoogle Scholar
• Vertegaal AC, Kuiperij HB, Yamaoka S, Courtois G, van der Eb AJ, Zantema A. Protein kinase C-α is an upstream activator of the IκB kinase complex in the TPA signal transduction pathway to NF-κB in U2OS cells. Cell. Signal. 12, 759–768 (2000).
   PubMedGoogle Scholar
• Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signaling. Nature 401, 86–90 (1999).
   PubMed Web of Science ®Google Scholar
• Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, Venuta S. Rapamycin inhibits doxorubin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur. J. Cancer 40(18), 2829–2836 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou L, Tan A, Iasvovskaia S, Li J, Lin A, Hershenson MB. Ras and mitogen-activated protein kinase kinase kinase-1 coregulate activator protein-1 and nuclear factor-kB-mediated gene expression in airway epithelial cells. Am. J. Resp. Cell. Mol. Biol. 28, 762–769 (2003).
   PubMed Web of Science ®Google Scholar
• Lin F, Zhang PL, Yang XJ, Prichard JW, Lun My, Brown RE. Overexpressed and activated mTOR pathway in renal cell carcinomas. Mod. Pathol. 18(Suppl. 1), 152A–153A (2005) (Abstract 705).
   Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr. Opin. Investig. Drugs. 4(6), 757–763 (2003).
   PubMedGoogle Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Weeraratna AT, Jiang Y, Hostetter G et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1(3), 279–288 (2002).
   PubMed Web of Science ®Google Scholar
• Jonsson M, Smith K, Harris AL. Regulation of Wnt5a expression in human mammary cells by protein kinase C activity and the cytoskeleton. Br. J. Cancer 78(4), 430–438 (1998).
   PubMedGoogle Scholar
• Cortes J, Thomas D, Koller C et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 10(10), 3371–3376 (2004).
   PubMed Web of Science ®Google Scholar
• Peralba JM, DeGraffenried L, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. 9(8), 2882–2886 (2003).
   PubMedGoogle Scholar
• Korf U, Wiemann S. Protein microarrays as a discovery tool for studying protein–protein interactions. Expert Rev. Proteomics 2(1), 13–26 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Shah MH, Young D, Kindler HL et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 10(18 Pt 1), 6111–6118 (2004).
   PubMed Web of Science ®Google Scholar
• Blaney SM, Bernstein M, Neville K et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a children’s oncology group study (ADVL0015). J. Clin. Oncol. 22(23), 4752–4757 (2004).
   Web of Science ®Google Scholar
• Zhang PL, Lun M, Siegelmann-Danieli N, Blasick TM, Brown RE. Pamidronate resistance and associated low Ras levels in breast cancer cells: a role for combinatorial therapy. Ann. Clin. Lab. Sci. 34(3), 263–270 (2004).
   PubMedGoogle Scholar
• Grunwald V, De Graffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62(21), 6141–6145 (2002).
   PubMed Web of Science ®Google Scholar
• Kamat AM, Karashima T, Davis DW et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol. Cancer Ther. 3(3), 279–290 (2004).
   PubMed Web of Science ®Google Scholar
• Merimsky O. Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation. Int. J. Mol. Med. 14(5), 931–935 (2004).
   PubMed Web of Science ®Google Scholar
• Mathew P, Thall PF, Jones D et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular Phase I trial in androgen-independent prostate cancer. J. Clin. Oncol. 22(16), 3323–3329 (2004).
   PubMed Web of Science ®Google Scholar
• van Waes C, Lebowitz P, Conley B, Gius D, Adams J, Sausville E. NF-κB and proteasome inhibition in therapy of head and neck cancer. 5th International Conference on Head and Neck Cancer, August 11–15th, Washington, DC, USA, (2004) (Abstract s202).
   Google Scholar
• Palmieri G, Lastoria S, Montella L et al. Role of somatostatin analogue-based therapy in unresponsive malignant thymomas. Ann. Med. 31(Suppl. 2), 80–85 (1999).
   PubMedGoogle Scholar
• Cattaneo MG, Scita G, Vicentini LM. Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells. FEBS Lett. 459(1), 64–68 (1999).
   PubMedGoogle Scholar